Skip to main content

Roche launches new coronavirus antibody test

| News

Roche launches new coronavirus antibody test


Roche is launching on the market a new antibody test to determine coronavirus infections. This should help with the development of vaccines. In addition, a drug from the Basel-based pharma giant has proven to be effective against coronavirus-associated pneumonia.

Roche Headquarter in Basel

Roche is launching a new antibody test that will identify people to have already been infected with coronavirus whose bodies have now developed antibodies against the virus. The test should help in developing vaccines against SARS-CoV-2. In specific terms, the test focuses on antibodies against the spike protein of SARS-CoV-2. The majority of vaccine candidates are aimed at inducing an antibody reaction against the spike protein.

The test will initially be launched in countries that accept that CE mark of the European Union (EU), as detailed in a press release. Roche has, however, also applied for Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA). The new test is actually the Basel-based pharma group’s twelfth coronavirus test in its testing portfolio.

In addition to launching a new test, Roche has also announced a success in relation to its drug Actemra/RoActemra. This has proven to be successful in treating patients suffering from pneumonia linked to a coronavirus infection. Patients that were administered Actemra/RoActemra in addition to the standard treatment, were 44 percent less likely to require ventilation or die as the disease progressed in comparison with those patients to receive only standard treatment and a placebo.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

The power of a persuasive pitch deck

Are you an entrepreneur striving to secure investment for your biotech startup? Start with an effective pitch deck to catch...
Read More

Roche investing an additional 1.2 billion Swiss francs in Basel

Roche will be putting an additional 1.2 billion Swiss francs towards the renovation of its site in Basel. This investment...
Read More

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

How to access the U.S. market with your medical device

In one of our latest Venture Mentoring events by Basel Are Business & Innovation, we invited Nila-Pia Rähle to speak...
Read More

Do you have a question? We'd like to hear from you.